Free tool
FAERS Monitor: Remodulin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021272 or its brand name (Remodulin, Treprostinil). Reports on generic versions are filed under their own applications.
Reports
65,346
Serious
41,979
64% of reports
Hospitalization
31,164
Death reported
9,061
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea9,904
- headache7,178
- diarrhoea6,904
- nausea6,212
- infusion site pain5,788
- death5,236
- fatigue4,101
- dizziness3,852
- vomiting3,407
- infusion site erythema3,353
- pain in extremity2,976
- hypotension2,834
- pulmonary arterial hypertension2,822
- malaise2,816
- pneumonia2,688
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 35 |
| 2005 | 62 |
| 2006 | 88 |
| 2007 | 43 |
| 2008 | 36 |
| 2009 | 71 |
| 2010 | 900 |
| 2011 | 1,625 |
| 2012 | 657 |
| 2013 | 1,002 |
| 2014 | 4,603 |
| 2015 | 5,481 |
| 2016 | 4,840 |
| 2017 | 4,855 |
| 2018 | 5,311 |
| 2019 | 4,970 |
| 2020 | 4,272 |
| 2021 | 4,041 |
| 2022 | 4,380 |
| 2023 | 5,081 |
| 2024 | 4,633 |
| 2025 | 4,928 |
| 2026 | 3,432 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,988,813 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion site painSignal | 5,788 | 261.4 | 252.7 | 828,128 |
| infusion site erythemaSignal | 3,353 | 211.8 | 202.9 | 423,913 |
| pulmonary arterial hypertensionSignal | 2,822 | 77.6 | 74.5 | 171,886 |
| dyspnoeaSignal | 9,904 | 5.7 | 5.6 | 38,882 |
| hypotensionSignal | 2,834 | 4.6 | 4.4 | 7,939 |
| headacheSignal | 7,178 | 3.7 | 3.6 | 14,517 |
| diarrhoeaSignal | 6,904 | 3.5 | 3.4 | 12,380 |
| pain in extremitySignal | 2,976 | 3.3 | 3.2 | 4,716 |
| pneumoniaSignal | 2,688 | 2.7 | 2.6 | 2,864 |
| nauseaSignal | 6,212 | 2.5 | 2.5 | 5,969 |
| dizzinessSignal | 3,852 | 2.5 | 2.4 | 3,513 |
| vomitingSignal | 3,407 | 2.3 | 2.3 | 2,659 |
| malaiseSignal | 2,816 | 2.1 | 2.0 | 1,587 |
| death | 5,236 | 2.0 | 1.9 | 2,559 |
| fatigue | 4,101 | 1.7 | 1.6 | 1,218 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.